AI-Powered Hormonal Biomarker Interpretation for Women's Reproductive Health: Clinical Validation of Multi-Parameter Analysis for Menstrual Disorders, Menopausal Transitions, and Gynecological Screening

Read full text Summarise with VIRAT
Authors: Thomas Klein, Sarah Mitchell, Hans U. Weber
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This peer-reviewed preprint presents the clinical validation of Kantesti AI's 2.78 trillion parameter neural network for multi-parameter hormonal biomarker interpretation in women's reproductive health. Analyzing 2,147,832 blood test results from women across 127+ countries (January 2024 – January 2026), the study evaluates AI-assisted interpretation accuracy across eight major gynecological domains: menopausal transition staging (STRAW+10 criteria), polycystic ovary syndrome (PCOS) biomarker pattern detection, menstrual disorder-related anemia identification, ovarian cyst risk stratification with CA-125 integration, thyroid-mediated menstrual irregularity detection, reproductive infection biomarker assessment, ovulation pattern recognition, and comprehensive gynecological screening panel interpretation. Key findings demonstrate 98.4% concordance with specialist gynecologist assessments for menopausal transition staging, 97.6% sensitivity for PCOS biomarker pattern detection, 98.1% accuracy for menstrual disorder-related anemia identification, and 96.8% concordance for ovarian cyst risk stratification. The system identified clinically significant multi-biomarker patterns in 23.7% of cases where individual biomarker values fell within conventional reference ranges — representing a meaningful advancement in preventive women's health care. The study addresses prevalent clinical concerns including nausea during ovulation, perimenopause gastrointestinal symptoms, ovarian cyst size danger thresholds (mm and cm), friable cervix differential diagnosis, ureaplasma infection management with concurrent partner treatment protocols, nighttime nausea in women, period weight gain physiology, brown semen (hematospermia) evaluation, and late period differential diagnosis. Validation was conducted through a triple-blind protocol involving 12 board-certified gynecologists and 8 reproductive endocrinologists across 6 countries. This research supports the integration of AI-assisted hormonal biomarker interpretation into clinical workflows as a complementary tool to specialist assessment, with particular value in primary care, telehealth, and resource-limited settings.Full companion clinical guide: Women's Health Guide: Ovulation, Menopause, Hormonal Symptoms & Reproductive Health — https://www.kantesti.net/womens-health-ovulation-menopause-hormonal-symptoms-guide/Authors: Thomas Klein, MD (Chief Medical Officer, Kantesti AI); Prof. Dr. Hans Weber, PhD (Senior Scientific Advisor, Kantesti AI); Dr. Sarah Mitchell, MD, PhD (Chief Medical Advisor, Kantesti AI)Corresponding Author: Thomas Klein, MD — info@kantesti.netPublisher: Kantesti AI (Kantesti Ltd, UK) — https://www.kantesti.net/

Fields of Study & Subjects

Artificial Intelligence in Healthcare Artificial Intelligence in Healthcare and Education Ovarian function and disorders

Publication details

Journal / source
Figshare
Publication date
1 January 2026
Language
EN
Document type
Preprint